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Summary. KindredVermont II has ahigh frequencyof venous
thrombosis, occurring primarily in pedigree members with type
I protein C deﬁciency due to a 3363 inserted (Ins) Cmutation in
exon 6 of the protein C gene. However, only a subset of 3363
InsC carriers have suﬀered thrombotic episodes, suggesting that
the increased risk of thrombosis results upon the co-occurrence
of 3363 InsCwith a second, unknown, thrombophilic mutation
that segregates independently within the pedigree. To test this
hypothesis and to localize the co-occurring gene, we performed
a genome scan of venous thrombosis in Kindred Vermont II.
Non-parametric linkage statistics identiﬁed three potential gene
locations, on chromosomes 11q23 (nominal P < 0.0001),
18p11.2-q11.2 (P < 0.0007), and 10p12 (P < 0.0003), sup-
porting the presence of at least one additional thrombophilic
mutation in the pedigree. Identiﬁcation of the unknown
mutation(s) promises to reveal a new genetic risk factor for
thrombophilia, contribute to our understanding of the blood
clottingmechanism, and expand our knowledge of the diversity
of oligogenic disease.
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Introduction
Venous thrombosis occurs with an annual incidence of 1–2 per
1000 [1]. Common risk factors include surgery, malignancy,
hyperhomocysteinemia, and high levels of procoagulant factor
II, factor (F)VIII, and factor XI, as well as several genetic
variants [2]. The high frequency of some genetic variants, in
particular factor (F)V Leiden [3] and prothrombin G20210A
[4], suggests oligogenic inheritance, that thrombophilia results
from the co-occurrence of two or more variants [5]. Oligogenic
inheritance can also explain the higher risk observed for speciﬁc
variants in individuals with a positive family history [6]. In fact,
oligogenic inheritance may be common, having recently been
demonstrated or proposed for a number of diseases [7,8].
Less common than either FV Leiden or prothrombin
G20210A, protein C deﬁciency, due to heterozygosity of any
of a number of mutations [9], increases thrombosis risk,
although most individuals with protein C deﬁciency are
asymptomatic [10]. Likewise, in a large Vermont pedigree
(Kindred Vermont II), a 3363 inserted (Ins) Cmutation in exon
6 of the protein C gene [11] increases, but appears insufﬁcient to
completely explain, venous thrombosis risk [12,13].
In some protein C-deﬁcient families, FV Leiden has been
identiﬁed as the co-occurring thrombophilic mutation [14], but
the presence of only four carriers rules out FV Leiden as a
major contributor in Kindred Vermont II. In contrast, 37
pedigree members carry prothrombin G20210A, but again we
ruled it out as the co-occurring mutation [15]. In addition, we
have ruled out prostaglandin H synthase 1 [16], a1-microglob-
ulin/bikunin precursor (AMBP) (unpublished data), and 34
other thrombosis candidate genes [17].
As an alternative to testing candidate genes, a genome scan
can localize novel genes not previously known to be involved in
the disease process. Here we present a genome scan of venous
thrombosis performed to identify potential regions for a genetic
mutation that co-occurs with 3363 InsC protein C to increase
risk of venous thrombosis in Kindred Vermont II.
Subjects and methods
The sample used in this analysis consists of a single large
pedigree, Kindred Vermont II, with a high rate of venous
thrombosis [12], partially attributable to type I protein C
deﬁciency due to 3363 InsC mutation in protein C [11]. All
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available descendants of a couple born in the 1800s were
studied; spouses were included whenever offspring were
available. The pedigree spans six generations with data
available on the most recent four. Pedigree members reside
primarily in Vermont and are descendants of French Canadi-
ans and Abenaki American Indians. This study was approved
by the Human Experimentation Committees of the University
of Vermont College of Medicine and Beth Israel Hospital,
Boston.
A total of 28 diagnoses of venous thrombosis were made,
each based on a self-report of hospitalization for treatment of
deep vein thromboembolism and conﬁrmation through objec-
tive tests. Median onset ages were 45 years (range 20–53 years)
in 12 male and 22 years (range17–76 years) in 15 female
descendants of the pedigree founders; one additional throm-
botic event occurred at age 71 years in the husband of a
pedigree member.
A total of 289 individuals were genotyped for 375 autosomal
markers by theNHLBIMammalianGenotyping Service at the
Marshﬁeld Medical Research Foundation [18] using Screening
Set version 10. Marker spacing averaged 9.4 cM (range
0–18 cM). Marker heterozygosity averaged 75% (range
42–89%). Using Eclipse2, the pairs version of Eclipse3 [19],
and multipoint information from all autosomal markers, we
identiﬁed 11 probable pedigree errors. The pedigree structure
was modiﬁed to reﬂect this information. Genotyping errors
were identiﬁed from multipoint genotypes using Simwalk2
[20,21] using input ﬁles produced by MEGA2 [22]. The
mistyping analysis identiﬁed 1389 genotypes ( 1% of the
total) having error probability ‡25%; each possibly erroneous
genotype was designated a missing value in all further analyses.
Using the pedigree structure corrected for likely errors and
marker genotypes eliminating likely errors, maximum likeli-
hood estimates of the marker allele frequencies were obtained
in PAP [23].
For the present analysis, the pedigree was reduced from 452
(289 genotyped) to 202 (132 genotyped) by eliminating
individuals who were both unaffected with thrombosis and
uninformative about the haplotypes of affected pedigree
members. Four non-parametric linkage statistics were compu-
ted using Simwalk2 [20] using input ﬁles produced byMEGA2
[22]. These statistics, designated A–D by Sobel and Lange [20]
and in the Simwalk2 documentation, are: (A) the number of
distinct haplotypes among affected individuals; (B) the highest
number of affected individuals with the same haplotype; (C)
entropy of haplotypes among the affected individuals; (D)
kinship among affected individuals. Statistic (A) is most
powerful for recessive diseases; statistic (B) is most powerful
for dominant diseases; Statistics (C) and (D) measure overrep-
resentation of a few haplotypes among affected pedigree
members. Multipoint linkage statistics A–D were computed at
each genome location of a genotyped marker.
Conservative nominal empiric P-values of each statistic were
produced by Simwalk2 by comparing the values of the statistics
to the unconditional distributions of the same statistics
ignoring marker phenotypes in the pedigree. Genome-wide
P-values of all four statistics simultaneously were estimated
through simulation. One thousand replicates of the 22 chro-
mosomes were simulated using the method of Terwilliger et al.
[24] as implemented in PAP [23]. Statistics A–Dwere computed
directly from the simulated haplotypes since the computer time
requirements prohibited the inference of haplotypes from
simulated marker genotypes; for each statistic, the mean for all
locations and replicates varied by <1% from the mean across
all locations of the expected values produced by SimWalk2.
The genome-wide P-value was estimated as the proportion of
replicates producing, for at least one location, more extreme
values of all four statistics than those obtained.
Additional markers in interesting chromosomal regions
were genotyped on 132 pedigree members using an ABI310
or 3100 at the Vermont Cancer Center DNA analysis facility.
Each added marker was positioned on the Marshﬁeld map
using relative locations on the physical map from the
National Center for Biotechnology Information (NCBI,
Build 33, April 2003) assembly, the GeneLoc map (Weiz-
mann Institute of Science), and/or the deCODE map [25].
The mistyping analyses, allele frequency estimation, and non-
parametric linkage analyses, as described above, were repea-
ted on each of the chromosomes, with the original and added
markers.
Results
Figure 1 presents the genome scan of venous thrombosis. Four
regions, on chromosomes 2, 10, 11, and 18, produced nominal
P < 0.01 for at least one of the four non-parametric linkage
statistics. As shown in Table 1, chromosomes 2 and 11 attained
signiﬁcant linkage (genome-wide P-value <0.05), while
chromosomes 10 and 18 attained suggestive linkage (genome-
wide P-value <1.0).
The region of chromosome 2 identiﬁed by the genome scan
(Fig. 1 and Table 1), contains the protein C gene [26].
Signiﬁcant linkage evidence on chromosome 2 was expected
since 3363 InsC protein C segregates in this pedigree [11] and
increases thrombosis risk [12,13]; 22 of the 28 thrombosis cases
in the pedigree are heterozygous for this mutation.
Chromosome 11 attained similar genome-wide and higher
nominal signiﬁcance than chromosome 2 (Fig. 1 and Table 1).
Because the frequencies of the thrombosis-associated D2S1334
and D11S1986 alleles were 32% and 9%, respectively, the
former occurred more often than the latter on non-thrombosis-
associated chromosomes of the parents of thrombosis cases,
reducing the multipoint linkage information and consequently
the signiﬁcance of the nominal P-values for chromosome 2. In
contrast, the assumption of full information when applied to
similar values for the statistics, produced similar genome-wide
P-values for chromosomes 2 and 11, with strong support from
statistics B, C, andD, and little support from statistic A, whose
strength lies with recessive diseases. The addition of 17 markers
on chromosome 11 strengthened the linkage evidence (Fig. 2
and Table 2). The implicated region ranges approximately
13 cM from D11S1778 to D11S4171.
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Chromosome 18 showed weaker linkage evidence than did
either chromosome 2 or 11 with a genome-wide P-value in the
suggestive range (Fig. 1 and Table 1). Again, support from
statistics B, C, andD, but not A, suggests dominant rather than
recessive inheritance. The addition of 23 markers to chromo-
some 18 strengthened the linkage evidence (Fig. 3 and
Table 2). The implicated region ranges about 24 cM across
the centromere from D18S542 to D18S877.
Chromosome 10 also showed genome-wide linkage evidence
in the suggestive range (Fig. 1 and Table 1). In contrast to the
other three regions, highest signiﬁcance was attained for
statistic A, which is most powerful for recessive inheritance.
The addition of 14 markers to chromosome 10 strengthened
the evidence produced by all the statistics (Fig. 4 and Table 2).
The implicated region ranges about 18 cM, from D10S1430 to
D10S1789.
Discussion
The 3363 InsC protein C mutation increases the risk of venous
thrombosis in Kindred Vermont II [11]. Nevertheless, only 15
of 39 mutation carriers over age 40 years have experienced a
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Fig. 1. Genome scan of venous thrombosis. Shown are P-values for non-parametric linkage statistics A (irregular), B (dashed), C (dotted), and D (solid)
by centimorgan (cM) based on the Marshﬁeld map for the 22 autosomes. See Subjects and methods for deﬁnitions of the statistics.
Table 1 Genome locations with nominal P < 0.01 for at least one non-parametric linkage statistic
Chromosome
Location*
(cM) Marker
P-value, nominal by linkage statistic
P-value,
genome-wideA B C D
2 145 D2S1334 0.2413 0.0112 0.0110 0.0061 0.046
10 46 D10S1423 0.0074 0.2133 0.0549 0.1710 0.668
11 106 D11S1986 0.0634 0.0010 0.0006 0.0003 0.043
18 41 D18S542 0.4993 0.0047 0.0282 0.0061 0.434
*Marshﬁeld map. See Subjects and methods for description.
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thrombotic episode, leading us to hypothesize that a second
thrombophilic mutation segregates independently withinKind-
red Vermont II, and that most thrombotic episodes in pedigree
members can be attributed to the co-occurrence of an unknown
mutation with protein C deﬁciency [13]. This genome scan
provides three strong candidate regions for the unknown
thrombophilic gene.
Of the three regions, chromosome 11q23 attained the highest
signiﬁcance both before and after ﬁnemapping. A shared
chromosome 11 haplotype was inferred for 18 thrombosis
cases, compared with 17 for the protein C region (where the
true number is 22). This suggests a risk from a chromosome 11
gene similar in magnitude to the risk from 3363 InsC. An
interesting candidate gene located within this region is the b
subunit of platelet-activating factor acetylhydrolase (PAF-
AH1B2) located at 11q23 [27]. PAF-AH1B2 downregulates
PAF at the cell surface [28] and thus, if deﬁcient, leads to
enhanced inﬂammatory response at the vascular wall with
likely increased local clotting activity. Dysregulation of PAF by
the plasma form of PAFAH located on chromosome 6p21 has
been associatedwith thrombotic and inﬂammatory disease [28].
A second candidate region, chromosome 18p11.2-q11.2,
provides a credible alternative to chromosome 11q23. Despite
lower signiﬁcance, 18 thrombosis cases were again inferred to
share a haplotype. Additional support for the region comes
from linkage of activated protein C resistance and, pleiotrop-
ically, FVIII and thrombosis in the Genetic Analysis of
Idiopathic Thrombophilia (GAIT) project [29]; their log of the
odds (lod) score peaked at D18S53, 2.3 cM on the Marshﬁeld
map from our linkage peak. Unfortunately, the chromosome
18 region contains no obvious candidate genes.
The third candidate region, chromosome 10p12, was iden-
tiﬁed by statistic A, which is most powerful for recessive
diseases. In contrast, both chromosomes 11q23 and 18p11.1-
q11.2 were identiﬁed by statistics most powerful for dominant
inheritance, thereby agreeing with our previous model-ﬁtting
[13]. Nevertheless, additional support for chromosome 10p12
derives from linkage of factor (F)XII in the GAIT project [30];
their lod score peaked at D10S1653, 5.3 cM on the Marshﬁeld
map from our linkage peak. Their failure to ﬁnd a corres-
ponding chromosome 10p12 effect on thrombosis risk may be
due to the absence in the GAIT pedigrees of an appropriate co-
occurring mutation, such as in protein C; FXII deﬁciency
increases risk of venous thrombosis [31].
Basedonearlier studyofapedigree subset, chromosome9q33
wasourstrongest candidate region.Consequently,we testedand
rejected as candidates prostaglandinH synthase 1 (PTGS1) [16]
and a1-microglobulin/bikunin precursor (AMBP) (unpublished
data).Thepresentanalysisproducedsuggestive linkageevidence
(genome-wide P < 0.812) on chromosome 9q33. Adding
PTGS1, AMBP, and ABO to the chromosome 9 map failed
to strengthen the weak linkage evidence (nominal P ¼ 0.016
before and P ¼ 0.019 after adding markers), eliminating
chromosome 9q33 from further consideration.
Of the three other candidate regions, we expect that two are
false positives, and that the thrombosis cases in the pedigree
result primarily from a single additional mutation that co-
occurs with protein C deﬁciency based on the ﬁt of the data to
that model [13]. However, each of the three candidate regions
has its strengths. The P-values most strongly support chromo-
some 11q23, but chromosome 18p11.2-q11.2 attained an
equivalent value of statistic B, and is supported by another
study. The recessive inheritance suggested by the chromosome
10p12 linkage was unexpected, but a chromosome 10 variant as
common as other thrombophilic variants and/or undetected
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Fig. 2. Fine-mapping of chromosome 11. Shown are P-values for
statistics B (long dashed), C (short dashed), and D (solid) by centimorgan
(cM) across the region identiﬁed in the genome scan.
Table 2 P-values for each genome location after ﬁne-mapping
Chromosome
Location*
(cM) Marker
Nominal P-value by
linkage statistic
A B C D
10 45 D10S1125 0.0003 0.0479 0.0047 0.0315
11 113 D11S1998 0.0687 0.0002 0.0002 0.0001
18 38 D18S1158 0.4237 0.0007 0.0032 0.0007
*Marshﬁeld map. See Subjects and methods for description.
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inbreeding might allow the clustering of multiple copies of an
allele within a pedigree. Alternatively,more than one additional
mutation may co-occur with protein C deﬁciency in this
pedigree. Since the dissection of the genes underlying oligogenic
diseases is in its infancy, characteristics of those genes remain to
be discovered.
Despite resulting from a single pedigree, we expect any
ﬁndings from this sample to apply to the population at large. In
fact, 3363 InsC protein C is common among protein C-
deﬁcient individuals in France and spread widely in Quebec
upon introduction by an immigrant French couple who settled
near Quebec City in 1669 [32]. Although the unknown
mutation may increase thrombosis risk only upon co-occur-
rence with 3363 InsC or only upon co-occurrence with any of
the manymutations that cause type I protein C deﬁciency [9], it
probably increases thrombosis risk upon co-occurrence with
any other thrombophilic mutation. If common, its discovery
could lead to an important new risk factor for thrombosis.
Even if rare, it promises to yield insight into the blood-clotting
mechanism. By limiting the sample to a single pedigree, we
simpliﬁed the well-documented complexity of thrombophilia,
obtained a large number of individuals with the identical
mutation, and increased the chances of only a single additional
thrombophilic mutation.
In summary, a genome scan has produced three candidate
regions for a gene that co-occurs with protein C deﬁciency to
increase the risk of venous thrombosis in a single large
pedigree. The identiﬁcation of the gene and its mutation will
increase understanding of the blood-clotting mechanism and
also presents an opportunity to understand a oligogenic
disease.
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